US Patent
US7449464 — Phthalazinone derivatives
Composition of Matter · Assigned to Kudos Pharmaceuticals Ltd · Expires 2027-09-08 · 1y remaining
Vulnerability score
17/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects novel phthalazinone derivatives, specifically compounds of the formula (I), which are fused aromatic ring systems with various substituents.
USPTO Abstract
Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NR<SUP>X </SUP>or CR<SUP>X</SUP>R<SUP>Y</SUP>; if X=NR<SUP>X </SUP>then n is 1 or 2 and if X=CR<SUP>X</SUP>R<SUP>Y </SUP>then n is 1; R<SUP>X </SUP>is selected from the group consisting of H, optionally substituted C<SUB>1-20 </SUB>alkyl, C<SUB>5-20 </SUB>aryl, C<SUB>3-20 </SUB>heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; R<SUP>Y </SUP>is selected from H, hydroxy, amino; or R<SUP>X </SUP>and R<SUP>Y </SUP>may together form a spiro-C<SUB>3-7 </SUB>cycloalkyl or heterocyclyl group; R<SUP>C1 </SUP>and R<SUP>C2 </SUP>are both hydrogen, or when X is CR<SUP>X</SUP>R<SUP>Y</SUP>, R<SUP>C1</SUP>, R<SUP>C2</SUP>, R<SUP>X </SUP>and R<SUP>Y</SUP>, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R<SUP>1 </SUP>is selected from H and halo.
Drugs covered by this patent
- Lynparza (olaparib) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.